Please login to the form below

Not currently logged in
Email:
Password:

Gilead's HIV drug meets phase III endpoint

A phase III clinical trial has shown Gilead's investigational antiretroviral agent elvitegravir is as effective as Merck's Isentress after 48 weeks

A phase III clinical trial has shown Gilead's investigational antiretroviral agent elvitegravir is as effective as Merck's Isentress after 48 weeks.

During the trial, elvitegravir was dosed once daily, compared to raltegravir, dosed twice daily. Both drugs were administered with a background regimen that includes a ritonavir-boosted protease inhibitor (PI) and a second antiretroviral agent. 

Gilead is studying the use of elvitegravir as part of a separate investigational fixed-dose, single-tablet "Quad" regimen. The Quad contains four Gilead compounds in a fixed-dose, single-tablet and is currently in phase III testing.

"We are very pleased to have achieved the primary endpoint in this clinical trial, as data from this study will support regulatory filings for elvitegravir as well as Gilead's investigational Quad pill," said Dr Norbert Bischofberger, executive vice president, R&D and chief scientific officer, Gilead Sciences. 

"By analysing these data now we will be in a better position to advance filings as quickly as possible once data from subsequent phase III clinical trials in our Quad development programme become available later this year."

The elvitegravir phase III, randomised, double-blind trial continues and will measure secondary endpoints including various additional measures of the efficacy, safety and tolerability of the two treatment regimens.

23rd March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics